NCT02964559View on ClinicalTrials.gov

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 27, 2017

Primary Completion Date

May 18, 2021

Study Completion Date

May 18, 2021

Conditions
Recurrent Skin CarcinomaSkin Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

30322

Emory University/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT02964559 - Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | Biotech Hunter | Biotech Hunter